| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 12/20/2001 | WO2001096283A2 Hiv integrase inhibitors |
| 12/20/2001 | WO2001095945A2 Prodrug compounds cleavable by thimet oligopeptidase |
| 12/20/2001 | WO2001095935A1 Immunostimulatory nucleic acids for inducing a th2 immune response |
| 12/20/2001 | WO2001095934A2 The use of plant oil-bodies in vaccine delivery systems |
| 12/20/2001 | WO2001095933A2 Immunization through oral administration of a vaccine with an edible product |
| 12/20/2001 | WO2001095932A1 A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR VIIa INHIBITOR |
| 12/20/2001 | WO2001095929A2 Interferon for treatment of multiple sclerosis |
| 12/20/2001 | WO2001095926A1 Immunosuppressor agent derived from morbillivirus |
| 12/20/2001 | WO2001095919A2 A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
| 12/20/2001 | WO2001095910A1 Imidazopyridine and imidazopyrimidine antiviral agents |
| 12/20/2001 | WO2001095908A1 Protoberberine derivatives which inhibit activity of the mitogen-activated protein kinase |
| 12/20/2001 | WO2001095905A1 Inhibitor for enzyme having two divalent metal ions as active centers |
| 12/20/2001 | WO2001095900A1 Pharmaceutical disinfectants comprising usnic and essential oils |
| 12/20/2001 | WO2001095896A2 Protein phosphatase 2a inhibitors to inhibit host-cell mediated viral replication |
| 12/20/2001 | WO2001095890A2 Oral pharmaceutical compositions containing terbinafine |
| 12/20/2001 | WO2001095887A1 Solid, orally administered, water-dispersible pharmaceutical form for the treatment of tuberculosis, containing rifampicin, isoniazid, pirazinamide and pyridoxine hydrochloride, method for obtaining and presentation form of said pharmaceutical form |
| 12/20/2001 | WO2001095884A2 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| 12/20/2001 | WO2001095878A1 Process for the preparation of a sterile ointment containing acyclovir |
| 12/20/2001 | WO2001095866A1 Hair oils |
| 12/20/2001 | WO2001095785A2 Modulation of immune response and methods based thereon |
| 12/20/2001 | WO2001088108A8 Neuronal serine-threonine protein kinase |
| 12/20/2001 | WO2001079259A8 Javelinization of protein antigens to heat shock proteins |
| 12/20/2001 | WO2001074788A8 2-hydroxy-mutilin carbamate derivatives for antibacterial use |
| 12/20/2001 | WO2001066550A3 Compounds for pdt |
| 12/20/2001 | WO2001064751A3 High potency recombinant antibodies and method for producing them |
| 12/20/2001 | WO2001058896A8 Benzoxazole derivatives as tnf and pde iv inhibitors |
| 12/20/2001 | WO2001056554A3 Use of retinoid-type compounds as antibacterial agents |
| 12/20/2001 | WO2001054719A3 Vaccine for the prophylactic or therapeutic immunization against hiv |
| 12/20/2001 | WO2001052888A3 Improved dna vaccines for production-type animals |
| 12/20/2001 | WO2001052874A3 Intra-tumoral administration of il-12 encoding nucleic acid molecules |
| 12/20/2001 | WO2001051456A3 Antibacterial agents |
| 12/20/2001 | WO2001051073A3 The parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| 12/20/2001 | WO2001049821A3 Th1 specific cd4 t cell lines and method for inducing them ex vivo |
| 12/20/2001 | WO2001049689A3 NOVEL SUBSTITUTED PYRAZOLO[4,3-e]DIAZEPINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, USE AS MEDICINAL PRODUCTS AND PROCESSES FOR PREPARING THEM |
| 12/20/2001 | WO2001048208A3 Streptococcus pyogenes virulence genes and proteins and their use |
| 12/20/2001 | WO2001047511A3 Treatment of drug-resistant human immunodeficiency virus infection |
| 12/20/2001 | WO2001046390A3 Method of inactivating microorganisms |
| 12/20/2001 | WO2001031016A3 Processed human chemokines phc-1 and phc-2 |
| 12/20/2001 | WO2000068387A3 Nucleic acids and proteins with interferon-beta activity |
| 12/20/2001 | WO2000066602A9 3-deoxy-desmycosin derivatives and process for their preparation |
| 12/20/2001 | WO2000024765A8 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 12/20/2001 | WO1999019304A3 Alpha-alkylthio substituted pyrimidine ethers and thioethers as viral reverse transcriptase inhibitors |
| 12/20/2001 | US20010053845 Anthracycline analogues bearing latent alkylating substituents |
| 12/20/2001 | US20010053800 Long chain monounsaturated alcohol mixtures |
| 12/20/2001 | US20010053796 Culture of fish in water tank |
| 12/20/2001 | US20010053794 Ionic polymers as anti-infective agents |
| 12/20/2001 | US20010053778 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 12/20/2001 | US20010053764 Interleukin-1 inhibitors in the treatment of diseases |
| 12/20/2001 | US20010053536 cDNA clone HDPBI30 that encodes a novel human 7-transmembrane receptor |
| 12/20/2001 | US20010053368 Proteosome influenza vaccine |
| 12/20/2001 | US20010053363 Novel amphipathic aldehydes and their uses as adjuvants and immunoeffectors |
| 12/20/2001 | US20010053351 Inhibition of GSK-3 beta |
| 12/20/2001 | DE10028402A1 New pyridinylamino-alkanoyl-glycyl-beta-alanine derivatives, are integrin inhibitors useful for treating, e.g. thrombosis, cardiac infarction, coronary heart disease, inflammation, tumors, osteoporosis or restenosis |
| 12/20/2001 | DE10027383A1 Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz Nucleic acid molecule comprising a sequence coding for a chemokine, a neuropeptide precursor or at least one neuropeptide nucleic acid sequence |
| 12/20/2001 | DE10024171A1 Neuronale Serin-Threonin-Protein-Kinase Neuronal serine threonine protein kinase |
| 12/20/2001 | CA2413077A1 Interferon for treatment of multiple sclerosis |
| 12/20/2001 | CA2412979A1 Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases |
| 12/20/2001 | CA2412857A1 Hiv integrase inhibitors |
| 12/20/2001 | CA2412632A1 Hmg-coa reductase inhibitors and method |
| 12/20/2001 | CA2412618A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| 12/20/2001 | CA2412579A1 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| 12/20/2001 | CA2412356A1 Immunosuppressor agent derived from morbillivirus |
| 12/20/2001 | CA2412343A1 Immunization through oral administration of a vaccine with an edible product |
| 12/20/2001 | CA2412327A1 Imidazopyridine and imidazopyrimidine antiviral agents |
| 12/20/2001 | CA2412257A1 Pro-apoptotic fragments of the dengue virus envelope glycoproteins |
| 12/20/2001 | CA2412165A1 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| 12/20/2001 | CA2411965A1 The use of plant oil-bodies in vaccine delivery systems |
| 12/20/2001 | CA2411472A1 Cd154 variants |
| 12/20/2001 | CA2411401A1 Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids |
| 12/20/2001 | CA2411036A1 Combinatorial production of nucleotide and nucleoside (xitp)analogues |
| 12/20/2001 | CA2410824A1 Diamino phenothiazine derivatives and composition comprising same |
| 12/20/2001 | CA2410610A1 Human kinases |
| 12/20/2001 | CA2410604A1 Use of coiled-coil structural scaffold to generate structure-specific peptides |
| 12/20/2001 | CA2410229A1 Vaccine for congenital tremors in pigs |
| 12/20/2001 | CA2410228A1 A combination product comprising melagatran and a factor viia inhibitor |
| 12/20/2001 | CA2409315A1 Protein phosphatases |
| 12/20/2001 | CA2396871A1 Immunostimulatory nucleic acids for inducing a th2 immune response |
| 12/19/2001 | EP1164196A1 Retroviral vectors |
| 12/19/2001 | EP1164188A1 Auxotrophic Mycobacterium mutants and tuberculosis vaccine |
| 12/19/2001 | EP1164135A1 Substituted metal-phthalocyanines, their preparation and the use thereof |
| 12/19/2001 | EP1164133A2 Enantiomerically pure Beta-D-(-)-dioxolane-nucleosides |
| 12/19/2001 | EP1163909A2 Use of sugar ethers as immunity adjuvant in vaccine compositions, therapeutic compositions containing them and their use as vaccine |
| 12/19/2001 | EP1163903A2 Methanal injection treatment for animal epidemics |
| 12/19/2001 | EP1163523A1 Method for detecting predisposition to a venous thromboembolic disease |
| 12/19/2001 | EP1163373A1 Antisense modulation of cellular inhibitor of apoptosis-1 expression |
| 12/19/2001 | EP1163356A1 Retroviral vectors comprising functional and non-functional splice donor and splice acceptor sites |
| 12/19/2001 | EP1163345A1 Fungal beta-tubulin genes |
| 12/19/2001 | EP1163342A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 12/19/2001 | EP1163336A2 Vertebrate protein slit, dna sequence encoding it and uses thereof |
| 12/19/2001 | EP1163334A1 Polynucleotide and deduced amino acid sequences from stromal cells |
| 12/19/2001 | EP1163332A1 48 human secreted proteins |
| 12/19/2001 | EP1163331A1 50 human secreted proteins |
| 12/19/2001 | EP1163267A1 47 human secreted proteins |
| 12/19/2001 | EP1163256A1 Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone |
| 12/19/2001 | EP1163255A1 50 human secreted proteins |
| 12/19/2001 | EP1163238A1 Chemokine recpetor binding heterocyclic compounds |
| 12/19/2001 | EP1163237A1 Amide derivatives |
| 12/19/2001 | EP1163234A1 Improved aqueous solubility pharmaceutical formulations |
| 12/19/2001 | EP1163226A1 Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity |
| 12/19/2001 | EP1163214A1 Gamma-ketoacid dipeptides as inhibitors of caspase-3 |